Purpose: Eradication of post-treatment residual myeloma cells is needed to prevent relapses and immunostimulatory monoclonal antibodies (mAbs) such as for example anti-CD137, CTLA-4, Compact disc40, etc, that improve the defense response against malignancies represent a way of achieving this purpose.…